Submicrometer silica particles for high-throughput separations of protein pharmac

用于蛋白质药物高通量分离的亚微米二氧化硅颗粒

基本信息

批准号：
8903976
负责人：
MARY J. WIRTH
金额：
$ 27.51万
依托单位：
PURDUE UNIVERSITY
依托单位国家：
美国
项目类别：
财政年份：
2012
资助国家：
美国
起止时间：
2012-04-01 至 2017-01-31
项目状态：
已结题

项目摘要

DESCRIPTION (provided by applicant): The proposed research is to increase the resolution per minute for protein separations. Faster protein separations are crucial to developing and formulating protein drugs because the separations are the bottleneck. Proteins, particularly monoclonal antibodies, are growing rapidly as a class of candidates in the pharmaceutical pipeline. Protein drugs promise higher specificity with fewer adverse effects, but protein heterogeneity can cause immunogenicity. Separations are required to analyze for heterogeneity. The low throughput of existing separations slows the optimizing of both protein production and drug formulation. The proposal is to increase throughput significantly by introducing extremely efficient separation media made of submicrometer particles with low-adsorptivity surfaces. Three major types of separations essential for protein drugs are addressed: 1) reversed phase chromatography for detecting small mass changes, 2) hydrophilic interaction chromatography for characterizing glycosylation, and 3) hydrodynamic chromatography for assessing aggregation. These separations will be tested with therapeutic monoclonal antibodies provided by Eli Lilly. The outcome of the research will be to speed drug development and advance drug safety for therapeutic monoclonal antibodies and other protein drugs. The enabling technology will broadly benefit research in the health sciences, including top-down proteomics, protein biomarker discovery, and basic research on disease mechanisms.

描述（由申请人提供）：拟议的研究是增加蛋白质分离的每分钟分辨率。更快的蛋白质分离对于开发和制定蛋白质药物至关重要，因为分离是瓶颈。蛋白质，尤其是单克隆抗体，作为药物管道中的一类候选者正在迅速生长。蛋白质药物有望更高的特异性，而不良反应较少，但蛋白质异质性可能会引起免疫原性。需要分离以分析异质性。现有分离的低通量会减慢蛋白质产生和药物制剂的优化。该提议是通过引入由具有低吸附性表面的亚微米颗粒制成的极有效的分离介质来显着增加吞吐量。蛋白质药物必不可少的三种主要类型的分离是提到：1）反向相反的相色谱法检测少量质量变化，2）用于表征糖基化的亲水相互作用色谱和3）3）流体动力色谱法用于评估聚集。这些分离将通过Eli Lilly提供的治疗单克隆抗体进行测试。这项研究的结果将是加快药物开发并提高治疗性单克隆抗体和其他蛋白质药物的药物安全。这项有利的技术将广泛受益于健康科学研究，包括自上而下的蛋白质组学，蛋白质生物标志物发现以及疾病机制的基础研究。